​

Funding Round

Series A - Amber Therapeutics

Series A - Amber Therapeutics

Investment Firm

Overview

Amber Therapeutics develops the next-generation of bioelectrical therapies.

Announced Date

Jun 10, 2024

Closed on Date

Jun 10, 2024

Funding Type

Series A

Highlights

Location

Europe

Social

Investor Lead

New Enterprise Associates

New Enterprise Associates

New Enterprise Associates is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.

Participant Investors

6

Investor Name
Participant InvestorOxford Science Enterprises
Participant InvestorLightstone Ventures
Participant InvestorF-Prime Capital
Participant Investor8VC
Participant InvestorNew Enterprise Associates

Round Details and Background

Amber Therapeutics raised $101703017 on 2024-06-10 in Series A

Amber Therapeutics develops the next-generation of bioelectrical therapies.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 24, 2023
Seed Round - Amber Therapeutics
2-undefined
Nov 29, 2022
Grant - Amber Therapeutics
1-1.3M
Jun 10, 2024
Series A - Amber Therapeutics
6-101.7M

Recent Activity

There is no recent news or activity for this profile.